Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer

Despite high response rates (RR) observed of up to 70% with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in treatment-naïve EGFR mutant non-small cell lung cancers (NSCLC), eliciting durable responses remains a perennial challenge.